QGEN Qiagen NV
1,401
$43.40
$0.46
(1.07%)
| Watchers | 1,401 |
| 52-Wk Low | $35.81 |
| 52-Wk High | $49.18 |
| Market Cap | $9.51B |
| Volume | 185,658.00 |
| 52-Wk High | $49.18 |
| 52-Wk Low | $35.81 |
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024Globe Newswire • about 1 month ago
Novel QIAcuity dPCR PanCancer Kits can detect rare mutations of EGFR and BRAF genes at the same time, while saving sample material, reducing time and cost // New QIAseq Targeted RNA-seq Panel for...
Share to Feed
In trading on Monday, shares of Qiagen NV (QGEN) crossed below their 200 day moving average of 42.88, changing hands as low as 42.82 per share. Qiagen NV shares are currently trading down...
QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced...
Joint educational initiative to focus on Interferon Gamma Release Assay (IGRA) benefits for healthcare providers // Updated U.S. CDC guidelines mandate IGRA testing for individuals aged 2 and older...
Venlo, the Netherlands, March 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited...
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Qiagen NV (QGEN), where a total volume of 5,610 contracts has been traded thus...
QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven drug discovery // AI-driven insights...
Additional ecofriendly QIAwave kits for DNA and RNA extraction receive ACT Label due to greatly improved Environmental Impact Factor compared to standard kits // QIAGEN's Sample technologies R&D lab...
Qiagen (NYSE:QGEN Free Report) Investment analysts at Zacks Research reduced their Q2 2024 EPS estimates for shares of Qiagen in a research report issued to clients and investors on...
Morgan Stanley upgraded shares of Qiagen (NYSE:QGEN Free Report) from an equal weight rating to an overweight rating in a research report released on Friday, Benzinga reports. The firm...